Intrinsic Therapeutics Receives PMA for Spinal Implant

The FDA granted Intrinsic Therapeutics’ premarket approval for its Barricaid anular closure device for reducing reherniation following the removal of a herniated disc.

The device is intended for skeletally mature patients with a pinched nerve, with or without back pain, from a posterior or posterolateral hernia.

The Barricaid device consists of a woven polyester occlusion component that is attached to the adjacent vertebral body with a titanium bone anchor.